These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1967513)

  • 1. Guanfacine: a second generation alpha 2-adrenergic blocker.
    Mosqueda-Garcia R
    Am J Med Sci; 1990 Jan; 299(1):73-6. PubMed ID: 1967513
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term treatment of hypertension with guanfacine alone and in combination therapy.
    Seedat YK
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):65S-66S. PubMed ID: 6994781
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.
    Jerie P
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):157S-164S. PubMed ID: 6994770
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of arterial hypertension with a single daily dose of guanfacine].
    Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC
    Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438
    [No Abstract]   [Full Text] [Related]  

  • 5. Guanfacine for hypertension.
    Med Lett Drugs Ther; 1987 May; 29(740):49-50. PubMed ID: 2883560
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of guanfacine and clonidine as antihypertensive agents.
    Jäättelä A
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6994782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.
    Sorkin EM; Heel RC
    Drugs; 1986 Apr; 31(4):301-36. PubMed ID: 3519177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with guanfacine in long-term treatment of hypertension.
    Jerie P
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):37S-47S. PubMed ID: 6994777
    [No Abstract]   [Full Text] [Related]  

  • 9. Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension.
    Manhem P; Hökfelt B
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):109S-114S. PubMed ID: 6994763
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy and tolerance of the antihypertensive agent guanfacine.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):170-4. PubMed ID: 6370876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind trial comparing guanfacine and methyldopa in patients with essential hypertension.
    Bune AJ; Chalmers JP; Graham JR; Howe PR; West MJ; Wing LM
    Eur J Clin Pharmacol; 1981; 19(5):309-15. PubMed ID: 7016550
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypotensive effect of guanfacine in essential hypertension: a comparison with clonidine.
    Lauro R; Reda G; Spallone L; Anguissola AB
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):81S-82S. PubMed ID: 6994784
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antihypertensive therapy with guanfacine. A multicenter study with Estulic-Wander 1mg. Determinants of effectiveness and tolerance].
    Schäfer N; Knaup G
    Med Welt; 1983 Feb; 34(5):158-61. PubMed ID: 6341756
    [No Abstract]   [Full Text] [Related]  

  • 15. [Minimal useful dose of guanfacine in patients with essential hypertension].
    Pérez Olea J; Ortíz N; Soledad Bertoló M; Allel L; Goity C; Quevedo M
    Rev Med Chil; 1985 May; 113(5):420-4. PubMed ID: 3912882
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ; Laszt A; Paran E; Ben Ari J; Goren Y; Modan M
    Neth J Med; 1987 Aug; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract]   [Full Text] [Related]  

  • 18. [The centrally acting antihypertensive drug guanfacine. Effect on lung function and circulatory parameters in hypertensive patients with bronchial asthma].
    Dorow P; Knaup G
    ZFA (Stuttgart); 1983 Sep; 59(27):1520-4. PubMed ID: 6359750
    [No Abstract]   [Full Text] [Related]  

  • 19. An ambulatory trial of guanfacine.
    Mann S; Millar Craig MW; Melville DI; Cashman PM; Raftery EB
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):103S-107S. PubMed ID: 6994762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of the antihypertensive action of long-term estulic (Egis-Sandoz) treatment.
    Zeher M; Antal L; Azad AQ; Szegedi G
    Ther Hung; 1988; 36(3):103-8. PubMed ID: 3074520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.